药物治疗抗精神病药所致锥体外系反应的进展
|
摘要
抗精神病药所致锥体外系反应(EPS)的临床症状多样,对患者的生活质量以及预后影响较大。针对EPS的治疗,常用药物有盐酸苯海索、普萘洛尔和苯二氮艹卓类药物,但均存在严重药物不良反应;多巴胺受体部分激动剂用于EPS的疗效已有部分机制方面与小样本临床研究证据的支持,但其临床疗效和安全性仍需更多基础研究和大样本量临床研究的证明;5-HT_(2A)受体拮抗剂对于静坐不能和类帕金森综合征可能有一定疗效并有高质量临床研究结果的支持,但对中国精神分裂症患者的疗效仍需验证;单胺类囊泡转运体Ⅱ受体拮抗剂对于抗精神病药所致的迟发性运动障碍(TD)具有良好疗效和安全性,在精神科的临床应用中有较大的价值。
引文
[1] DIVAC N, PROSTRAN M, JAKOVCEVSKI I, et al.Second-generation antipsychotics and extrapyramidal adverse effects[J]. Biomed Res Int,2014,2014:656370.
[2] PELUSO M J, LEWIS S W, BARNES T R, et al.Extrapyramidal motor side-effects of first-and second-generation antipsychotic drugs [J].Br J Psychiatry,2012,200(5):387.
[3] SAVICA R, GROSSARDT BR, BOWER JH, et al. Incidence and time trends of drug-induced parkinsonism: a 30-year population-based study[J]. Mov Disord,2017,32(2):227.
[4] MILLER D D, CAROFF S N, DAVIS S M, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial [J].Br J Psychiatry,2008,193(4):279.
[5] JESIC M P,JESIC A, FILIPOVIC J B, et al. Extrapyramidal syndromes caused by antipsychotics[J].Med Pregl,2012,65(11/12):521.
[6] 张云淑, 严保平, 栗克清. 精神分裂症患者抗胆碱能药物使用现状及影响因素分析[J]. 中国临床药理学杂志,2016.32(13):1234.
[7] FOX C, SMITH T, MAIDMENT I, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review[J]. Age,2014,43(5):604.
[8] VINOGRADOV S, FISHER M, WARM H, et al.The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia [J]. Am J Psychiatry,2009,166(9):1055.
[9] WALN O, JANKOVIC J. An update on tardive dyskinesia: from phenomenology to treatment[J]. Tremor Other Hyperkinet Mov (N Y). 2013,3. pii: tre-03-161-4138-1.
[10] STAHL S M. Mechanism of action of cariprazine[J]. CNS Spectrums,2016,21(2):123.
[11] HSU W Y, LANE H Y, UN C H. Brexpiprazole for the treatment of schizophrenia[J]. Expert Opin Pharmacother,2017,18(2):217.
[12] MILLAN M J,LOISEAU F, DEKEYNE A, et al. S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects[J]. J Pharmacol Exp Ther,2008,324(3):1212.
[13] KANE J M, ZUKIN S, WANG Y, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase Ⅲ clinical trial[J]. J Clin Psychopharmacol,2015,35(4):367.
[14] KOSMOWSKA B, WARDAS J, GLOWACKA U, et al. Pramipexole at a low dose induces beneficial effect in the harmaline-induced model of essential tremor in rats[J]. CNS neurosci ther,2016,22(1):53.
[15] FERGER B, BUCK K, SHIMASAKI M, et al. Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson’s disease: a pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats[J]. Synapse,2010 ,64(7):533.
[16] Di FABIO R, De FILIPPIS S, CAFARIELLO C, et al. Low doses of rotigotine in patients with antipsychotic-induced parkinsonism[J]. Clin Neuropharmacol,2013,36(5):162.
[17] KELLEHER J P, CENTORRINO F, HUXLEY N A, et al. Pilot randomized, controlled trial of pramipexole to augment antipsychotic treatment[J]. Eur Neuropsychopharmacol,2012,22(6):415.
[18] ALEX K D, PEHEK E A. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission[J]. Pharmacol Ther, 2007,113(2):296.
[19] CASEY D E. Pathophysiology of antipsychotic drug-induced movement disorders[J]. J Clin Psychiatry,2004,65(Suppl 9):25.
[20] POYUROVSKY M, WEIZMAN A. Treatment of antipsychotic-related akathisia revisited: the role of serotonin 2A receptor antagonists[J]. J Clin Psychopharmacol,2015,35(6):711.
[21] POYUROVSKY M, PASHINIAN A, WEIZMAN R, et al. Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. a randomized, double-blind, placebo-and propranolol-controlled trial[J]. Biol Psychiatry,2006,59(11):1071.
[22] STRYJER R, ROSENZCWAIG S, BAR F, et al. Trazodone for the treatment of neuroleptic-induced acute akathisia: a placebo-controlled, double-blind, crossover study[J]. Clin Neuropharmacol,2010,33(5):219.
[23] LAOUTIDIS Z G, LUCKHAUS C. 5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis[J].Int J Neuropsychopharmacol,2014,17(5):823
[24] SHIREEN E, HALEEM D J. Reversal of haloperidol-induced motor deficits by mianserin and mesulergine in rats[J]. Pak J Pharm Sci,2011,24(1):7.
[25] JANKOVIC J. Dopamine depeters in the treatment of hyperkinetic movement disorders[J]. Expert Opin Pharmacother,2016,17(18):2461.
[26] DAVIS M C, MILLER B J, KALSI J K, et al. Efficient trial design-FDA approval of valbenazine for tardive dyskinesia[J]. N Engl J Med,2017,376(26):2503.
[27] O’BRIEN C F, JIMENEZ R, HAUSER R A, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study[J]. Mov Disord,2015,30(12):1681.
[28] HAUSER R A, FACTOR S A, MARDER S R, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia[J]. AmeJ Psychiatry,2017,174(5):47.
[29] ANDERSON K E, STAMLER D, Davis M D, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Psychiatry,2017,4(8):595 .
[2] PELUSO M J, LEWIS S W, BARNES T R, et al.Extrapyramidal motor side-effects of first-and second-generation antipsychotic drugs [J].Br J Psychiatry,2012,200(5):387.
[3] SAVICA R, GROSSARDT BR, BOWER JH, et al. Incidence and time trends of drug-induced parkinsonism: a 30-year population-based study[J]. Mov Disord,2017,32(2):227.
[4] MILLER D D, CAROFF S N, DAVIS S M, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial [J].Br J Psychiatry,2008,193(4):279.
[5] JESIC M P,JESIC A, FILIPOVIC J B, et al. Extrapyramidal syndromes caused by antipsychotics[J].Med Pregl,2012,65(11/12):521.
[6] 张云淑, 严保平, 栗克清. 精神分裂症患者抗胆碱能药物使用现状及影响因素分析[J]. 中国临床药理学杂志,2016.32(13):1234.
[7] FOX C, SMITH T, MAIDMENT I, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review[J]. Age,2014,43(5):604.
[8] VINOGRADOV S, FISHER M, WARM H, et al.The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia [J]. Am J Psychiatry,2009,166(9):1055.
[9] WALN O, JANKOVIC J. An update on tardive dyskinesia: from phenomenology to treatment[J]. Tremor Other Hyperkinet Mov (N Y). 2013,3. pii: tre-03-161-4138-1.
[10] STAHL S M. Mechanism of action of cariprazine[J]. CNS Spectrums,2016,21(2):123.
[11] HSU W Y, LANE H Y, UN C H. Brexpiprazole for the treatment of schizophrenia[J]. Expert Opin Pharmacother,2017,18(2):217.
[12] MILLAN M J,LOISEAU F, DEKEYNE A, et al. S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects[J]. J Pharmacol Exp Ther,2008,324(3):1212.
[13] KANE J M, ZUKIN S, WANG Y, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase Ⅲ clinical trial[J]. J Clin Psychopharmacol,2015,35(4):367.
[14] KOSMOWSKA B, WARDAS J, GLOWACKA U, et al. Pramipexole at a low dose induces beneficial effect in the harmaline-induced model of essential tremor in rats[J]. CNS neurosci ther,2016,22(1):53.
[15] FERGER B, BUCK K, SHIMASAKI M, et al. Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson’s disease: a pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats[J]. Synapse,2010 ,64(7):533.
[16] Di FABIO R, De FILIPPIS S, CAFARIELLO C, et al. Low doses of rotigotine in patients with antipsychotic-induced parkinsonism[J]. Clin Neuropharmacol,2013,36(5):162.
[17] KELLEHER J P, CENTORRINO F, HUXLEY N A, et al. Pilot randomized, controlled trial of pramipexole to augment antipsychotic treatment[J]. Eur Neuropsychopharmacol,2012,22(6):415.
[18] ALEX K D, PEHEK E A. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission[J]. Pharmacol Ther, 2007,113(2):296.
[19] CASEY D E. Pathophysiology of antipsychotic drug-induced movement disorders[J]. J Clin Psychiatry,2004,65(Suppl 9):25.
[20] POYUROVSKY M, WEIZMAN A. Treatment of antipsychotic-related akathisia revisited: the role of serotonin 2A receptor antagonists[J]. J Clin Psychopharmacol,2015,35(6):711.
[21] POYUROVSKY M, PASHINIAN A, WEIZMAN R, et al. Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. a randomized, double-blind, placebo-and propranolol-controlled trial[J]. Biol Psychiatry,2006,59(11):1071.
[22] STRYJER R, ROSENZCWAIG S, BAR F, et al. Trazodone for the treatment of neuroleptic-induced acute akathisia: a placebo-controlled, double-blind, crossover study[J]. Clin Neuropharmacol,2010,33(5):219.
[23] LAOUTIDIS Z G, LUCKHAUS C. 5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis[J].Int J Neuropsychopharmacol,2014,17(5):823
[24] SHIREEN E, HALEEM D J. Reversal of haloperidol-induced motor deficits by mianserin and mesulergine in rats[J]. Pak J Pharm Sci,2011,24(1):7.
[25] JANKOVIC J. Dopamine depeters in the treatment of hyperkinetic movement disorders[J]. Expert Opin Pharmacother,2016,17(18):2461.
[26] DAVIS M C, MILLER B J, KALSI J K, et al. Efficient trial design-FDA approval of valbenazine for tardive dyskinesia[J]. N Engl J Med,2017,376(26):2503.
[27] O’BRIEN C F, JIMENEZ R, HAUSER R A, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study[J]. Mov Disord,2015,30(12):1681.
[28] HAUSER R A, FACTOR S A, MARDER S R, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia[J]. AmeJ Psychiatry,2017,174(5):47.
[29] ANDERSON K E, STAMLER D, Davis M D, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Psychiatry,2017,4(8):595 .